Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4835-4839

  Duong, Duy An ^a   Duyen, Nguyen Thi Hong ^a   Lan, Nguyen Thi Ngoc ^b   Dai, Viet Hoa ^b   Ha, Dang Thi Minh ^a,b   Vo, Sy Kiet ^a   Thu, Do Dang Anh ^a   Chau, Nguyen Van Vinh ^a,d   Nguyen, Huy Dung ^b   Dinh, Ngoc Sy ^e   Farrar, Jeremy ^a,c   Caws, Maxine ^a,c  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b Pham Ngoc Thach Hospital   (Viet Nam)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e National TB Control Program   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ISONIAZID; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHINA; CONTROLLED STUDY; DNA POLYMORPHISM; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VIET NAM;

EID: 70350290476     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00541-09     Document Type: Article

References (32)

1. Anh, D. D., M. W. Borgdorff, L. N. Van, N. T. Lan, T. van Gorkom, K. Kremer, and D. van Soolingen. 2000. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg. Infect. Dis. 6:302-305.
2. Caws, M., G. Thwaites, S. Dunstan, T. R. Hawn, N. T. Lan, N. T. Thuong, K. Stepniewska, M. N. Huyen, N. D. Bang, T. H. Loc, S. Gagneux, D. van Soolingen, K. Kremer, M. van der Sande, P. Small, P. T. Anh, N. T. Chinh, H. T. Quy, N. T. Duyen, D. Q. Tho, N. T. Hieu, E. Torok, T. T. Hien, N. H. Dung, N. T. Nhu, P. M. Duy, N. van Vinh Chau, and J. Farrar. 2008. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4:e1000034. (Pubitemid 351631085)
3. Caws, M., G. Thwaites, K. Stepniewska, T. N. Nguyen, T. H. Nguyen, T. P. Nguyen, N. T. Mai, M. D. Phan, H. L. Tran, T. H. Tran, D. van Soolingen, K. Kremer, V. V. Nguyen, T. C. Nguyen, and J. Farrar. 2006. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J. Clin. Microbiol. 44:3934-3939.
4. Dale, J. W., D. Brittain, A. A. Cataldi, D. Cousins, J. T. Crawford, J. Driscoll, M. Meersma, T. Lilleback, T. Quituyua, and N. Rastogi. 2001. Spacer oligonucleotide typing of bacteria of the Mycobacterium tuberculosis complex: recommendations for standard nomenclature. Int. J. Tuberc. Lung 5:216-219.
5. Dewan, P., A. Sosnovskaja, V. Thomsen, J. Cicenaite, K. Laserson, I. Johansen, E. Davidaviciene, and C. Wells. 2005. High prevalence of drugresistant tuberculosis, Republic of Lithuania, 2002. Int. J. Tuberc. Lung Dis. 9:170-174.
6. Dooley, K. E., J. Golub, F. S. Goes, W. G. Merz, and T. R. Sterling. 2002. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin. Infect. Dis. 34:1607-1612.
7. Escribano, I., J. C. Rodriguez, B. Llorca, E. Garcia-Pachon, M. Ruiz, and G. Royo. 2007. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 53:397-401. (Pubitemid 350085252)
8. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. 2006. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12:736-743.
9. Gagneux, S., K. DeRiemer, T. Van, M. Kato-Maeda, B. C. de Jong, S. Narayanan, M. Nicol, S. Niemann, K. Kremer, M. C. Gutierrez, M. Hilty, P. C. Hopewell, and P. M. Small. 2006. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103:2869-2873.
10. Gillespie, S. H., and N. Kennedy. 1998. Fluoroquinolones: a new treatment for tuberculosis? Int. J. Tuberc. Lung Dis. 2:265-271.
11. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
12. Grimaldo, E. R., T. E. Tupasi, A. B. Rivera, M. I. Quelapio, R. C. Cardano, J. O. Derilo, and V. A. Belen. 2001. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5:546-550.
13. Hegde, S. S., M. W. Vetting, S. L. Roderick, L. A. Mitchenall, A. Maxwell, H. E. Takiff, and J. S. Blanchard. 2005. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308:1480-1483. (Pubitemid 40791304)
14. Hillemann, D., T. Kubica, S. Rusch-Gerdes, and S. Niemann. 2005. Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob. Agents Chemother. 49:1229-1231.
15. Huong, N. T., B. D. Duong, N. V. Co, H. T. Quy, L. B. Tung, M. Bosman, A. Gebhardt, J. P. Velema, J. F. Broekmans, and M. W. Borgdorff. 2005. Establishment and development of the National Tuberculosis Control Programme in Vietnam. Int. J. Tuberc. Lung Dis. 9:151-156.
16. Jassal, M., and W. R. Bishai. 2009. Extensively drug-resistant tuberculosis. Lancet Infect. Dis. 9:19-30.
17. Kamerbeek, J., L. Schouls, A. Kolk, M. van Agterveld, D. van Soolingen, S. Kuijper, A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. van Embden. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914.
18. Long, R., H. Chong, V. Hoeppner, H. Shanmuganathan, K. Kowalewska-Grochowska, C. Shandro, J. Manfreda, A. Senthilselvan, A. Elzainy, and T. Marrie. 2009. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin. Infect. Dis. 48:1354-1360.
19. Matrat, S., N. Veziris, C. Mayer, V. Jarlier, C. Truffot-Pernot, J. Camuset, E. Bouvet, E. Cambau, and A. Aubry. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob. Agents Chemother. 50:4170-4173.
20. Mokrousov, I., O. Narvskaya, T. Otten, E. Limeschenko, L. Steklova, and B. Vyshnevskiy. 2002. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob. Agents Chemother. 46:1417-1424.
21. Mokrousov, I., T. Otten, O. Manicheva, Y. Potapova, B. Vishnevsky, O. Narvskaya, and N. Rastogi. 2008. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52:2937-2939.
22. Quy, H. T., T. N. Buu, F. G. Cobelens, N. T. Lan, C. S. Lambregts, and M. W. Borgdorff. 2006. Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 10:160-166.
23. Rad, M. E., P. Bifani, C. Martin, K. Kremer, S. Samper, J. Rauzier, B. Kreiswirth, J. Blazquez, M. Jouan, D. van Soolingen, and B. Gicquel. 2003. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg. Infect. Dis. 9:838-845.
24. Sterling, T. R. 2004. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int. J. Tuberc. Lung Dis. 8:1396-1400.
25. Sun, Z., J. Zhang, X. Zhang, S. Wang, Y. Zhang, and C. Li. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
26. van Soolingen, D., P. E. de Haas, H. R. van Doorn, E. Kuijper, H. Rinder, and M. W. Borgdorff. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in The Netherlands. J. Infect. Dis. 182:1788-1790.
27. Vree, M., D. D. Bui, N. S. Dinh, V. C. Nguyen, M. W. Borgdorff, and F. G. Cobelens. 2007. Tuberculosis trends, Vietnam. Emerg. Infect. Dis. 13:796-797.
28. Wang, J. Y., P. R. Hsueh, I. S. Jan, L. N. Lee, Y. S. Liaw, P. C. Yang, and K. T. Luh. 2006. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 61:903-908.
29. World Health Organization. 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB2006. World Health Organization, Geneva, Switzerland.
30. Yoon, Y. S., H. J. Lee, H. I. Yoon, C. G. Yoo, Y. W. Kim, S. K. Han, Y. S. Shim, and J. J. Yim. 2005. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int. J. Tuberc. Lung Dis. 9:1215-1219.
31. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525.
32. Ziganshina, L. E., and S. B. Squire. 2007. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst. Rev. 2007(4):CD004795. doi:10.1002/14651858.CD004795.pub3.